MabSpace and Jiangsu Hengrui Collaborate on mAb Development

MabSpace Biosciences, a Hong Kong-Suzhou antibody discovery company, has signed a collaborative contract with Jiangsu Hengrui Medicine to co-develop novel antibody therapeutics on two targets. MabSpace will discover and select humanized lead antibodies using its proprietary immune tolerance breaking technology. Hengrui will be responsible for later development and own exclusive global rights to the candidates. More details.... Stock Symbol: (SHZ: 200513) Share this with colleagues: // //